ECSP067029A - NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS - Google Patents
NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOSInfo
- Publication number
- ECSP067029A ECSP067029A EC2006007029A ECSP067029A ECSP067029A EC SP067029 A ECSP067029 A EC SP067029A EC 2006007029 A EC2006007029 A EC 2006007029A EC SP067029 A ECSP067029 A EC SP067029A EC SP067029 A ECSP067029 A EC SP067029A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorders
- sexual
- disorder
- sexual dysfunction
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 2
- 206010024419 Libido decreased Diseases 0.000 abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 2
- 208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 2
- 206010002652 Anorgasmia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 1
- 229940052760 dopamine agonists Drugs 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 208000014840 female orgasmic disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 201000004197 inhibited female orgasm Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de fórmula (I): que son una clase de agonistas de dopamina, más particularmente una clase de agonistas que son selectivos para D3 sobre D2. Estos compuestos son útiles para el tratamiento y/o prevención de la disfunción sexual, por ejemplo la disfunción sexual femenina (FSD), en particular el trastorno de la excitación sexual femenina (FSAD), trastorno del deseo sexual hipoactivo (HSDD; falta de interés en el sexo), trastorno orgásmico femenino (FOD; incapacidad para alcanzar el orgasmo); y la disfunción sexual masculina, en particular la disfunción eréctil masculina (MED). La disfunción sexual masculina según se refiere en la presente memoria se supone que incluye trastornos eyaculatorios tales como eyaculación precoz, anorgasmia (incapacidad para alcanzar el orgasmo) o trastornos del deseo tales como el trastorno del deseo sexual hipoactivo (HSDD; falta de interés en el sexo). Estos compuestos también son útiles para tratar trastornos neuropsiquiátricos y trastornos neurodegenerativos.The present invention provides compounds of formula (I): which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and / or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to reach orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is supposed to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to reach orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). These compounds are also useful for treating neuropsychiatric disorders and neurodegenerative disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP067029A true ECSP067029A (en) | 2006-12-29 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006007029A ECSP067029A (en) | 2004-05-27 | 2006-11-27 | NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (en) |
| JP (1) | JP4198183B2 (en) |
| AP (1) | AP2006003824A0 (en) |
| AR (1) | AR049548A1 (en) |
| AU (1) | AU2005247699A1 (en) |
| BR (1) | BRPI0511571A (en) |
| CA (1) | CA2567935C (en) |
| EA (1) | EA200601982A1 (en) |
| EC (1) | ECSP067029A (en) |
| GT (1) | GT200500125A (en) |
| IL (1) | IL179314A0 (en) |
| MA (1) | MA28607B1 (en) |
| MX (1) | MXPA06013786A (en) |
| NL (1) | NL1029139C2 (en) |
| NO (1) | NO20065326L (en) |
| PA (1) | PA8635101A1 (en) |
| PE (1) | PE20060366A1 (en) |
| SV (1) | SV2005002129A (en) |
| TW (1) | TW200609216A (en) |
| UY (1) | UY28925A1 (en) |
| WO (1) | WO2005115985A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| KR20110114663A (en) * | 2009-02-13 | 2011-10-19 | 바이엘 파마 악티엔게젤샤프트 | Fused Pyrimidine |
| AU2011240773C1 (en) * | 2010-04-12 | 2015-08-27 | Supernus Pharmaceuticals Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| WO2013003769A2 (en) | 2011-06-30 | 2013-01-03 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and, methods |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| JP7030776B2 (en) | 2016-07-20 | 2022-03-07 | ノバルティス アーゲー | Use as aminopyridine derivatives and their selective ALK-2 inhibitors |
| MA51020B1 (en) * | 2017-12-08 | 2021-10-29 | Boehringer Ingelheim Int | Imidazopyridine compounds and their use as a medicine |
| EP3953350A1 (en) * | 2019-04-12 | 2022-02-16 | The United States of America, as Represented by The Department of Health and Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| BR112022009710A2 (en) | 2019-11-22 | 2022-08-09 | Incyte Corp | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR |
| CA3187767A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| PT1572214E (en) * | 2002-12-10 | 2010-05-06 | Pfizer | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction |
-
2005
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/en not_active Application Discontinuation
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/en not_active Application Discontinuation
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/en not_active Expired - Fee Related
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/en unknown
- 2005-05-17 EA EA200601982A patent/EA200601982A1/en unknown
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en not_active Ceased
- 2005-05-24 GT GT200500125A patent/GT200500125A/en unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/en not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/en unknown
- 2005-05-26 AR ARP050102169A patent/AR049548A1/en unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/en not_active Application Discontinuation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/en unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/en not_active IP Right Cessation
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/en not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/en unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/en unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2567935A1 (en) | 2005-12-08 |
| AU2005247699A1 (en) | 2005-12-08 |
| JP4198183B2 (en) | 2008-12-17 |
| PE20060366A1 (en) | 2006-05-15 |
| IL179314A0 (en) | 2007-03-08 |
| NL1029139A1 (en) | 2005-11-30 |
| TW200609216A (en) | 2006-03-16 |
| BRPI0511571A (en) | 2008-01-02 |
| WO2005115985A1 (en) | 2005-12-08 |
| CA2567935C (en) | 2009-10-27 |
| JP2008500331A (en) | 2008-01-10 |
| AR049548A1 (en) | 2006-08-16 |
| NO20065326L (en) | 2006-12-19 |
| EP1758862A1 (en) | 2007-03-07 |
| GT200500125A (en) | 2006-01-10 |
| AP2006003824A0 (en) | 2006-12-31 |
| EA200601982A1 (en) | 2007-04-27 |
| UY28925A1 (en) | 2005-12-30 |
| MXPA06013786A (en) | 2007-01-25 |
| SV2005002129A (en) | 2005-12-13 |
| NL1029139C2 (en) | 2006-06-19 |
| MA28607B1 (en) | 2007-05-02 |
| PA8635101A1 (en) | 2006-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001426A1 (en) | New compounds of 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidin-2,7-dione for the treatment and prophylaxis of viral infections. | |
| CL2017000864A1 (en) | Compositions and methods of use to treat metabolic disorders | |
| DOP2016000140A (en) | SYK INHIBITORS | |
| PE20190973A1 (en) | TETRAHYDROPIRAZOLOPIRIMIDINE COMPOUNDS | |
| CL2016000341A1 (en) | Methods to treat myositis by sporadic inclusion bodies | |
| CL2016000436A1 (en) | Method for the treatment of fibrotic disease | |
| CL2012002905A1 (en) | Compounds derived from heteroaryl-cyclohexyl-tetraazabenzo (e) substituted azanes, vasopressin v1a receptor modulators; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, anxiety, among others. | |
| UY35682A (en) | ANTI-ACTIVINE ANTIBODIES A AND USES OF THE SAME | |
| PA8819201A1 (en) | DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JAK INHIBITORS | |
| PE20170899A1 (en) | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS GPR MODULATORS 139 | |
| MX2019009908A (en) | COMBINATION OF A PPAR AGONIST WITH AN FXR AGONIST. | |
| CU20200041A7 (en) | SUBSTITUTE IMIDAZOPYRIDINE AMIDES | |
| CL2020001107A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine derivatives as p2x3 inhibitors. | |
| MX2022011972A (en) | COMPOSITIONS COMPRISING ANTIBODIES AGAINST IL6R FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA, AND METHODS OF USE THEREOF. | |
| CL2015003195A1 (en) | Purine derivatives as cb2 receptor agonists. | |
| CL2017003133A1 (en) | Use of benzimidazole derivatives for night acid escape | |
| PA8635101A1 (en) | NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS | |
| CU24647B1 (en) | MODULATORS OF THE HETEROAROMATIC NMDA RECEPTOR | |
| CL2012002954A1 (en) | Compounds derived from substituted heterobaryl-cyclohexyl-tetraazabenzo [e], modular vasopressin v1a receptor; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, anxiety, hypertension, among others. | |
| EA201391702A1 (en) | INTRANASAL TESTOSTERONIC COMPOSITIONS WITH REDUCED DOSAGE IN THE FORM OF GEL AND THEIR USE FOR THE TREATMENT OF ANORGASMASIS OR HYPOACTIVE DISORDER | |
| PE20181450A1 (en) | 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| SV2011003784A (en) | NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDA | |
| DOP2005000095A (en) | NEW DERIVATIVES OF AMINOPIRIDINE AND ITS USE AS PHARMACOS | |
| ECSP067024A (en) | NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS | |
| MX2022000356A (en) | COMPOUND FOR COMBINATION TREATMENT. |